Barclays PLC Purchases 61,554 Shares of Enfusion, Inc. (NYSE:ENFN)

Barclays PLC lifted its stake in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 251.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 86,039 shares of the company's stock after purchasing an additional 61,554 shares during the quarter. Barclays PLC owned 0.07% of Enfusion worth $817,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ENFN. Scalar Gauge Management LLC grew its stake in Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company's stock worth $5,227,000 after buying an additional 110,000 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Enfusion by 6.7% during the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company's stock worth $9,265,000 after acquiring an additional 61,032 shares during the period. Renaissance Technologies LLC boosted its position in shares of Enfusion by 167.6% during the 2nd quarter. Renaissance Technologies LLC now owns 97,100 shares of the company's stock worth $827,000 after acquiring an additional 60,811 shares in the last quarter. PDT Partners LLC bought a new position in Enfusion in the third quarter valued at approximately $867,000. Finally, Squarepoint Ops LLC acquired a new position in Enfusion during the second quarter valued at approximately $683,000. Institutional investors own 81.05% of the company's stock.

Insider Activity

In related news, COO Neal Pawar sold 21,801 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Bradley Herring sold 24,443 shares of Enfusion stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $10.61, for a total value of $259,340.23. Following the transaction, the chief financial officer now directly owns 270,503 shares in the company, valued at $2,870,036.83. The trade was a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,918 shares of company stock valued at $484,037. 36.44% of the stock is currently owned by corporate insiders.

Enfusion Price Performance

ENFN stock traded down $0.17 during midday trading on Wednesday, reaching $10.30. 317,063 shares of the stock were exchanged, compared to its average volume of 392,888. Enfusion, Inc. has a 52 week low of $7.52 and a 52 week high of $11.38. The company has a fifty day moving average price of $9.95 and a 200 day moving average price of $9.10. The stock has a market capitalization of $1.32 billion, a PE ratio of 257.56, a P/E/G ratio of 3.98 and a beta of 0.97.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Piper Sandler lifted their price target on Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a research note on Monday, December 23rd. Stifel Nicolaus lifted their target price on Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $10.25.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.